Table 2.
Association of TIM-3+ iTILs with other immune biomarkers in breast cancer.
| Immune biomarkers | TIM-3+ iTILs = 0 (n = 2816) |
TIM-3+ iTILs ≥ 1 (n = 332) |
P-value (χ2) |
|---|---|---|---|
| PD-L1* | |||
| Negative | 2374 | 215 (8%) | < 0.0001 |
| Positive (≥ 1%) | 133 | 97 (42%) | |
| PD-1+ iTILs* | |||
| Negative | 2388 | 198 (8%) | < 0.0001 |
| Positive (≥ 1) | 127 | 113 (47%) | |
| LAG-3+ iTILs* | |||
| Negative | 2344 | 169 (7%) | < 0.0001 |
| Positive (≥ 1) | 175 | 146 (45%) | |
| CD8+ iTILs* | |||
| Negative | 1881 | 111 (6%) | < 0.0001 |
| Positive (≥ 1) | 778 | 213 (22%) |
*Frequency in the whole cohort: PD-L1 ≥ 1% = 241/2918 (8.3%); PD-1+ iTILs ≥ 1 = 246/2908 (8.5%); LAG-3+ iTILs = 327/2921 (11%), from Burugu S et al., Annals of Oncology, 2017. CD8+ iTILs ≥ 1 = 1089/3403 (32%) from Liu S et al., Breast Cancer Research, 2012)